BioSight
Companies
BioAge Labs, Inc. logo

BIOA

NASDAQEMERYVILLE, CA
BioAge Labs, Inc.

BioAge Labs develops small-molecule drug candidates targeting aging-related diseases, with a current focus on BGE-102 for atherosclerotic cardiovascular disease risk reduction and diabetic macular edema, as well as APJ receptor programs. BGE-102 is currently in Phase 1 clinical trials, with the organization working toward obtaining regulatory approvals and eventual commercialization of these product candidates.

Price history not yet available for BIOA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar